Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)

Annals of the Rheumatic Diseases

Volumn 61, Issue 10, 2002, Pages 922-924

  Arzoo, K ^a   Sadeghi, S ^a   Liebman, H A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; CRYOGLOBULINEMIA; DISEASE COURSE; DRUG MECHANISM; FEMALE; GOODPASTURE SYNDROME; HUMAN; IMMUNE COMPLEX DISEASE; KIDNEY FUNCTION; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; PLASMAPHERESIS; PRIORITY JOURNAL; SKIN MANIFESTATION; TREATMENT OUTCOME;

AGED; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; AUTOIMMUNE DISEASES; CRYOGLOBULINEMIA; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNE COMPLEX DISEASES; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; MALE; VASCULITIS;

EID: 0036785195     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.61.10.922     Document Type: Article

References (15)

1. Tarantino A, De Vecchi A, Montagnino G, Imbasciati E, Mihatsch MJ, Zollinger HU, et al. Renal disease in essential mixed cryoglobulinemia. Long-term follow-up of 44 patients. Q J Med 1981;50:1-30.
2. Lockwood CM, Rees AJ, Pearson TA, Evans DJ, Peters DK, Wilson CB. Immunosuppression and plasma exchange in the treatment of Goodpasture's syndrome. Lancet 1976;1:711-15.
3. DeVita S, Neri R, Bombardieri S. Cyclophosphamide pulses in the treatment of rheumatic diseases, an update. Clin Exp Rheumatol 1991;9:179-93.
4. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
5. Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF, et al. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen activated, and malignant B lymphocytes. J Immunol 1983;131:244-50.
6. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-CDB8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapse low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
7. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998;91:1644-52.
8. Byrd JC, White CA, Link B, Lucas MS, Velasquez WS, Rosenberg J, et al. Rituximab therapy in previously treated Walderstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999;10:1525-7.
9. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999;52:1701-4.
10. Saleh MN, Gutheil J, Moore M, Bunch PW, Butler J, Kunkel L, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000;27:99-103.
11. Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonoal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 2001;97:3995-7.
12. Edwards JCW, Cambridge G, Abrahams VM. Do self-perpetuating B-lymphocytes drive human autoimmune disease? Immunology 1999;97:188-96.
13. Gonzalez-Stawinski GV, Yu PB, Love SD, Parker W, Davis D. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody. Clin Immunol 2001; 98:175-9.
14. Zaja F, Russo D, Fuga G, Patriarca F, Ermacora A, Baccarani M. Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 1999;84:1157-8.
15. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11.